Clinical research
The science behind NeuroQ
NeuroQ has been studied as a complete formula — not just one ingredient — in randomized,
placebo-controlled clinical trials in North America and Japan. Here's what the research found.
Research Partner: KGK Science, 2024
A randomized, triple-blind, placebo-controlled clinical trial investigating the safety and
efficacy of NeuroQ on cognitive function in healthy North American adults (ages 40–79) with self-reported
memory problems. Eighty participants took NeuroQ or placebo for 60 days. Cognition was measured
objectively with CNS Vital Signs (Neurocognitive Index) and subjectively with the Everyday Memory
Questionnaire.
Conclusion
NeuroQ produced early and sustained improvements in cognition compared with placebo.
Participants taking NeuroQ showed significant gains in the Neurocognitive Index after just 7 days, and
these improvements were maintained through 60 days. Within the first week, the NeuroQ group also showed
significant improvements in verbal memory, complex attention, and psychomotor speed relative to placebo,
and reported improvements in everyday memory from baseline at Day 60. NeuroQ was safe and well tolerated.
As the first randomized, placebo-controlled trial to show NeuroQ significantly outperforming placebo on
objective cognition in a North American population, these findings support further study in clinical
populations.
Final study report prepared by KGK Science, September 2024. (Protocol 23LSCNF01.)
Research Partner: Yamada Bee Company Group (Japan), 2020
A placebo-controlled, randomized, parallel-group, double-blind clinical study of the NeuroQ
formulation (propolis extract, Ginkgo biloba extract, phosphatidylserine, and curcumin) in 90 healthy mid-
to senior-age Japanese adults (ages 40–79) over 12 weeks.
Conclusion
Compared with placebo, the NeuroQ group showed significant improvements in attention,
concentration, and judgment (Stroop commission errors), in verbal memory and attention (MCI-screen MPI
score), and in immediate recall. Participants also showed reduced inflammation (TNF-α), along with improved
sleep quality and social functioning. Benefits were most pronounced among participants with low baseline
BDNF, a marker associated with higher risk of cognitive decline. No serious adverse events were observed,
and the supplement was found to be safe and effective.
Published in the peer-reviewed journal “Japanese Pharmacology & Therapeutics”
(Jpn Pharmacol Ther), 2020.
Research Partner: KGK Science, 2021
KGK Science conducted an open-label study to evaluate the efficacy of Dr. Bredesen's PreCODE
Protocol and LifeSeasons' NeuroQ supplement in supporting cognition in healthy adults with risk factors for
cognitive decline. Since Alzheimer's Disease (AD) and other dementias are multifactorial disorders, a
multidimensional approach was used in the current study.
Conclusion
NeuroQ and the PreCODE Protocol combined to show significantly improved cognitive function,
quality of life, daytime sleepiness, and mood in adults at risk of cognitive decline. Improvements in
cognitive function were evident 30 days after initiating the lifestyle intervention and improvements in
quality of life, including general health, energy, pain, physical functioning, and sleep reported after 90
days. Placebo- or comparator-controlled studies are warranted to confirm these findings.
Manuscript under peer review for scientific publishing.
